Skip to content

Study on the modulatory effects of stimulating the foot-sanli (ST-36) acupoint on gastric pain-related brain regions in patients with chronic gastritis

Study on the modulatory effects of stimulating the foot-sanli (ST-36) acupoint on gastric pain-related brain regions in patients with chronic gastritis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001234
Enrollment
Unknown
Registered
2025-06-21
Start date
2025-04-08
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic gastritis

Interventions

Treatment group 1:Electroacupuncture bilateral ST-36
Treatment group 2:Transcranial magnetic stimulation combined with electroacupuncture of bilateral ST-36

Sponsors

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) The included patients met the diagnostic criteria for patients with chronic gastritis disease (mild to moderate). All patients excluded other immune diseases and stress diseases and were in remission (relapsing-remitting type). (2) 18 years = age = 85 years both male and female. (3) Have gastroscopy in the last six months to one year or have the willingness to receive gastroscopy after enrollment. (4) Patients can be treated with western medicine as well as Chinese medicine methods (electroacupuncture). (5) Have certain comprehension and reading ability and be able to correctly understand the relevant contents of the scale and respond to it. (6) Good compliance and willingness to cooperate with the study and patients signed the informed consent form. (7) The process of obtaining informed consent complies with the relevant provisions of the Good Clinical Practice (GCP).

Exclusion criteria

Exclusion criteria: (1) Patients with a history of gastrointestinal surgery; (2) Patients with gastric cancer and other gastric diseases; (3) Patients with the presence of severe heart liver and kidney function diseases; (4) Patients with the presence of functional insufficiency of important organs of the body; (5) Patients who cannot be needled or patients who cannot tolerate needling therapy or transcranial magnetic stimulation therapy; (6) Taking drugs that promote gastrointestinal motility; (7) Patients with concurrent moxibustion therapy; (8) Patients with any clinically significant history of disease or other significant primary and psychiatric disorders (i) HIV infection or active hepatitis A or syphilis infection; history or signs of immunodeficiency; ii) epilepsy that is not adequately controlled by treatment; iii) clinically significant cardiac disorders such as uncontrolled arrhythmias uncontrolled angina pectoris cardiomyopathy or uncontrolled congestive heart failure; iv) history of severe (iv) History of severe depression or suicide attempts or current suicidal ideation; (v) History of malignant neoplastic disease patients with a history of hepatitis B etc.); (9) Patients who are pregnant or breastfeeding or who have a pregnancy plan within the last 3 months; (10) Those who are participating in other studies. Note: Patients who fulfill any 1 of the above items will be excluded.

Design outcomes

Primary

MeasureTime frame
VAS;PGI;EGG;G-17;PGII;

Secondary

MeasureTime frame
Chinese Medicine Symptom Rating Scale;

Countries

China

Contacts

Public ContactZhangFan

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

21152828@qq.com13693415738

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026